Immune Pharmaceuticals Portfolio
IMMUNE Pharmaceuticals is emerging leader in developing Monoclonal Antibodies and Ligand-conjugated Nanoparticles (NanomAbs®) based products for a broad range of therapeutic applications, including solid tumors and hematological malignancies, autoimmune, inflammatory and infectious diseases.
IMMUNE is rapidly developing its lead programs, starting Phase 2 human clinical trial for its lead product candidate Bertilimumab in 2012 and 2013. The first Phase 2 clinical study of Bertilimumab is a double-blind, placebo-controlled, fixed dose, multi-centered study in to evaluate the safety, efficacy and pharmacokinetics in patients with active moderate to severe Ulcerative Colitis. More information on this trial can be found at ClinicalTrials.gov. Results from this initial Phase 2 study are expected to be reported in the fourth quarter of 2013.
IMMUNE's portfolio includes additional proprietary product candidates in research and preclinical development for cancer, autoimmune, and inflammatory diseases. The developed platforms of NanomAbs® for active cellular based therapy and specific targeting have already proven successful in animal models of several medical indications.